Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 1.82
SVA's Cash to Debt is ranked higher than
60% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. SVA: 1.82 )
SVA' s 10-Year Cash to Debt Range
Min: 0.48   Max: No Debt
Current: 1.82

Equity to Asset 0.54
SVA's Equity to Asset is ranked higher than
63% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. SVA: 0.54 )
SVA' s 10-Year Equity to Asset Range
Min: 0.41   Max: 0.64
Current: 0.54

0.41
0.64
F-Score: 3
Z-Score: 2.67
M-Score: -2.40
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -42.98
SVA's Operating margin (%) is ranked higher than
72% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. SVA: -42.98 )
SVA' s 10-Year Operating margin (%) Range
Min: -35600   Max: 50.06
Current: -42.98

-35600
50.06
Net-margin (%) -30.18
SVA's Net-margin (%) is ranked higher than
74% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. SVA: -30.18 )
SVA' s 10-Year Net-margin (%) Range
Min: -39700   Max: 23.7
Current: -30.18

-39700
23.7
ROE (%) -12.62
SVA's ROE (%) is ranked higher than
75% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -21.87 vs. SVA: -12.62 )
SVA' s 10-Year ROE (%) Range
Min: -175.76   Max: 28.25
Current: -12.62

-175.76
28.25
ROA (%) -7.11
SVA's ROA (%) is ranked higher than
78% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. SVA: -7.11 )
SVA' s 10-Year ROA (%) Range
Min: -180.3   Max: 13.72
Current: -7.11

-180.3
13.72
ROC (Joel Greenblatt) (%) -23.95
SVA's ROC (Joel Greenblatt) (%) is ranked higher than
79% of the 872 Companies
in the Global Biotechnology industry.

( Industry Median: -196.35 vs. SVA: -23.95 )
SVA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1507.41   Max: 161.87
Current: -23.95

-1507.41
161.87
Revenue Growth (%) -22.90
SVA's Revenue Growth (%) is ranked higher than
63% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -1.30 vs. SVA: -22.90 )
SVA' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 81.7
Current: -22.9

0
81.7
» SVA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

SVA Guru Trades in Q1 2013

Jim Simons 345,800 sh (+6.83%)
Chris Davis 2,627,231 sh (unchged)
Chuck Royce 573,711 sh (-67.21%)
» More
Q2 2013

SVA Guru Trades in Q2 2013

Jim Simons 393,600 sh (+13.82%)
Chris Davis 2,627,231 sh (unchged)
Chuck Royce Sold Out
» More
Q3 2013

SVA Guru Trades in Q3 2013

Jim Simons 896,600 sh (+127.79%)
Chris Davis 1,473,343 sh (-43.92%)
» More
Q4 2013

SVA Guru Trades in Q4 2013

Jim Simons 1,054,996 sh (+17.67%)
Chris Davis 1,178,606 sh (-20%)
» More
» Details

Insider Trades

Latest Guru Trades with SVA



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.80
SVA's P/B is ranked higher than
76% of the 791 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. SVA: 2.80 )
SVA' s 10-Year P/B Range
Min: 0.73   Max: 11.83
Current: 2.8

0.73
11.83
P/S 4.85
SVA's P/S is ranked higher than
74% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 10.27 vs. SVA: 4.85 )
SVA' s 10-Year P/S Range
Min: 0.98   Max: 71.11
Current: 4.85

0.98
71.11
EV-to-EBIT 17.90
SVA's EV-to-EBIT is ranked higher than
59% of the 468 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. SVA: 17.90 )
SVA' s 10-Year EV-to-EBIT Range
Min: 1.4   Max: 39.2
Current: 17.9

1.4
39.2
Shiller P/E 103.70
SVA's Shiller P/E is ranked lower than
61% of the 175 Companies
in the Global Biotechnology industry.

( Industry Median: 38.74 vs. SVA: 103.70 )
SVA' s 10-Year Shiller P/E Range
Min: 15.09   Max: 182
Current: 103.7

15.09
182

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 15.10
SVA's Price/Net Current Asset Value is ranked lower than
61% of the 525 Companies
in the Global Biotechnology industry.

( Industry Median: 9.60 vs. SVA: 15.10 )
SVA' s 10-Year Price/Net Current Asset Value Range
Min: 3.37   Max: 109
Current: 15.1

3.37
109
Price/Tangible Book 2.80
SVA's Price/Tangible Book is ranked higher than
80% of the 736 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. SVA: 2.80 )
SVA' s 10-Year Price/Tangible Book Range
Min: 0.9   Max: 14.04
Current: 2.8

0.9
14.04
Price/DCF (Projected) 8.60
SVA's Price/DCF (Projected) is ranked lower than
66% of the 210 Companies
in the Global Biotechnology industry.

( Industry Median: 2.80 vs. SVA: 8.60 )
SVA' s 10-Year Price/DCF (Projected) Range
Min: 0.96   Max: 8.54
Current: 8.6

0.96
8.54
Price/Median PS Value 1.00
SVA's Price/Median PS Value is ranked higher than
66% of the 725 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. SVA: 1.00 )
SVA' s 10-Year Price/Median PS Value Range
Min: 0.25   Max: 3.79
Current: 1

0.25
3.79
Earnings Yield (Greenblatt) 5.60
SVA's Earnings Yield (Greenblatt) is ranked higher than
67% of the 378 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. SVA: 5.60 )
SVA' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.5   Max: 69.6
Current: 5.6

2.5
69.6
Forward Rate of Return (Yacktman) 0.51
SVA's Forward Rate of Return (Yacktman) is ranked higher than
88% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. SVA: 0.51 )
SVA' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -7.3   Max: 1.1
Current: 0.51

-7.3
1.1

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:SVQ.Germany
Sinovac Biotech Ltd. formerly known as Net-Force System Inc. was incorporated in Antigua and Barbuda on March 1, 1999. It is a holding company and conducts its business in China through its 73.09% majority-owned subsidiary, Sinovac Beijing, and its wholly owned subsidiaries, Tangshan Yian, Sinovac Biological, Sinovac Hong Kong and 30%-owned joint venture Sinovac Dalian. It is a China-based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases. Its portfolio of regulatory approved products consists of vaccines against the hepatitis A, hepatitis B and influenza viruses. In 2002, the Company launched its first product, Healive, which was the first inactivated hepatitis A vaccine developed, produced and marketed in China. It is administered intramuscularly and is available in a 1.0 ml dose for adults and a 0.5 ml dose for children. In 2005, the Company received regulatory approvals in China for the production of Bilive, which is a combined vaccine formulated by purified inactivated hepatitis A virus antigen, available from Healive, and the recombinant yeast-derived hepatitis B surface antigen. Bilive is used to prevent infection from hepatitis A and hepatitis B. Bilive is available in different doses for use in both adults and children. The 1.0ml dose is for non-immune adults and adolescents 16 years of age and older. The Company's Anflu vaccine is an inactivated split influenza vaccine formulated from three split inactivated virus solutions. Anflu is standardized annually according to the virus strains recommended by WHO for the current year. In April 2008, the Company was granted a production license for Panflu by the China State Food and Drug Administration (SFDA). Panflu is the first and only approved vaccine available in China against the H5N1 influenza virus. Under the production license for Panflu granted by SFDA, the vaccine is solely approved for supply to the Chinese national vaccine stockpiling program and would not be sold directly to the commercial market. The Company's pipeline consists of vaccine candidates in the pre-clinical and clinical development phases in China, including human vaccines for the EV71, Japanese encephalitis and rabies currently in pre-clinical development, a vaccine for the SARS virus that has completed a Phase I clinical trial and a split viron vaccine for the H5N1 influenza virus that has completed a Phase II clinical trial. Its pipeline also includes a vaccine for rabies in animals that is currently in field trials. Its competitors include large pharmaceutical, biotechnology companies and academic research institutions, both domestic and international.The Company is subject to PRC laws and regulations governing the use, manufacture, storage, handling or disposal of hazardous materials and waste products.
» More Articles for NAS:SVA

Headlines

Articles On GuruFocus.com
No related article found.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide